UK – iFAST Diagnostics, a pioneering UK diagnostics company announces the successful close of its $6.5 million (£5 million) seed round.

英国–英国领先的诊断公司iFAST Diagnostics宣布其650万美元（500万英镑）的种子轮成功结束。

iFAST has developed a cutting-edge technology that tests bacteria to determine the most effective antibiotics in under three hours. This is a significant advancement compared to the current 48-72 hours required. Using a microchip to analyse thousands of bacteria electrically, the system ensures that patients get the right treatment faster, potentially saving lives, especially in critical cases like sepsis and drug-resistant infections..

iFAST开发了一种尖端技术，可以在三小时内测试细菌以确定最有效的抗生素。与目前所需的48-72小时相比，这是一个重大进步。该系统使用微芯片对数千种细菌进行电子分析，确保患者更快地获得正确的治疗，有可能挽救生命，尤其是在脓毒症和耐药性感染等危重病例中。。

The oversubscribed round was led by KHP Ventures, the first NHS-anchored venture fund, with existing investors Qantx, UKI2S (Managed by Future Planet Capital), Kadmos, and angels reaffirming their commitment. New investors EInk, RAW Ventures, and OKG Capital have joined, underscoring the significant market potential of iFAST’s breakthrough technology..

这轮超额认购由第一家NHS锚定风险基金KHP Ventures牵头，现有投资者Qantx、UKI2S（由Future Planet Capital管理）、Kadmos和angels重申了他们的承诺。新投资者EInk、RAW Ventures和OKG Capital也加入进来，突显了iFAST突破性技术的巨大市场潜力。。

Toby King, CEO of iFAST, commented on the raise: “We are incredibly excited to receive the investment we need to bring our technology to market just a couple of years after founding the company. The thought of saving patients’ lives through them having the correct antibiotic at the right time is hugely motivating for the whole team.

iFAST首席执行官托比·金（Toby King）对此次加薪表示：“我们非常高兴能在公司成立几年后获得将我们的技术推向市场所需的投资。通过在正确的时间使用正确的抗生素来挽救患者生命的想法极大地激励了整个团队。

I’d like to thank all our existing investors for continuing to support us, and KHP in particular for leading the round, as well as EInk, RAW, and OKG for having the conviction to come on board at this pivotal time for our business.”.

我要感谢所有现有投资者继续支持我们，特别是KHP领导了这一轮，以及EInk、RAW和OKG坚信在这个关键时刻加入我们的业务。”。

Tim Irish, Partner at KHP Ventures, said: “iFAST is ideally placed to tackle the ever-increasing global threat of antimicrobial resistance. The technology is 10x faster than the current gold standard for AST while maintaining the same levels of accuracy, throughput, and cost. We are excited to partner with iFAST and concurrently help the NHS achieve its 5-year plan to combat antimicrobial resistance.”.

KHP Ventures合伙人蒂姆·爱尔兰（TimIrish）表示：“iFAST非常适合应对日益增长的全球抗菌素耐药性威胁。该技术比目前的AST金标准快10倍，同时保持相同的准确性，吞吐量和成本水平。我们很高兴与iFAST合作，同时帮助NHS实现其对抗抗菌素耐药性的5年计划。”。

Richard Haycock, CEO of Qantx, added: “We are proud to continue our support for iFAST Diagnostics as they build technology to transform the way clinicians identify and treat antibiotic-resistant infections. The amazing progress the team has made in the last 18 months is a testament to their hard work, and we’re excited to see their solution be made available to hospitals in the UK, Europe, and the US with this investment.”.

Qantx首席执行官理查德·海考克（Richard Haycock）补充道：“我们很自豪继续支持iFAST诊断，因为他们正在构建技术，以改变临床医生识别和治疗抗生素耐药性感染的方式。该团队在过去18个月取得的惊人进展证明了他们的辛勤工作，我们很高兴看到他们的解决方案能够通过这项投资提供给英国、欧洲和美国的医院。”。

The proceeds from this round will be used to bring iFAST’s rapid Antimicrobial Susceptibility Testing (AST) platform to market in the UK in early 2025, with launches in the US and EU soon after. The platform delivers both qualitative and quantitative results in under three hours, a massive improvement over the 48-72 hours required by current gold-standard methods.

这一轮的收益将用于2025年初在英国将iFAST的快速抗菌药物敏感性测试（AST）平台推向市场，之后不久将在美国和欧盟推出。该平台在不到三个小时的时间内提供了定性和定量结果，比当前金标准方法所需的48-72小时有了巨大改进。

This speed could dramatically improve patient outcomes, especially for life-threatening infections like sepsis and MRSA..

这种速度可以显着改善患者的预后，特别是对于危及生命的感染，如败血症和MRSA。。

Hassan Mahmudul, Investment Manager at UKI2S (managed by Future Planet Capital) spoke about its follow on investment: “iFAST’s progress is exceptional. Since our initial investment, the team has demonstrated the ability to translate groundbreaking research into a scalable solution.

UKI2S（由Future Planet Capital管理）的投资经理哈桑·马哈茂德（Hassan Mahmudul）谈到了其后续投资：“iFAST的进展非常出色。自我们最初投资以来，该团队已经证明了将开创性研究转化为可扩展解决方案的能力。

“This funding marks a pivotal step toward transforming patient outcomes globally. At UKI2S, we specialise in catalysing growth for early-stage companies, unlocking significant downstream investment and accelerating innovations that address critical healthcare challenges.

“这笔资金标志着在全球范围内改变患者结果的关键一步。在UKI2S，我们专注于促进早期公司的增长，解锁重要的下游投资，并加速解决关键医疗保健挑战的创新。

“We are proud to continue supporting iFAST as it tackles antimicrobial resistance head-on, a mission that aligns perfectly with our commitment to impactful and economically transformative technologies.”

“我们很自豪能够继续支持iFAST正面应对抗菌素耐药性，这一使命与我们对具有影响力和经济变革性技术的承诺完全一致。”